Autoantibodies to amyloid-beta and Alzheimer's disease

Ann Neurol. 2001 Jun;49(6):808-10. doi: 10.1002/ana.1061.

Abstract

Immunization against amyloid-beta has been suggested as a possible preventive or therapeutic treatment for Alzheimer's disease. We hypothesized that some individuals may have autoantibodies to amyloid-beta and that this may be protective. We analyzed the plasma of 365 individuals, drawn from a larger longitudinal epidemiological study, for the presence of antibodies to amyloid-beta. There were detectable but very low levels of anti-amyloid-beta antibodies in just over 50% of all samples and modest levels in under 5% of all samples. However, neither the presence nor the level of anti-amyloid-beta antibodies correlated with the likelihood of developing dementia or with plasma levels of amyloid-beta peptide. These data suggest that low levels of anti-amyloid-beta autoantibodies are frequent in the elderly population but do not confer protection against developing dementia.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Aged
  • Alzheimer Disease / blood
  • Alzheimer Disease / etiology
  • Alzheimer Disease / immunology*
  • Amyloid beta-Peptides / immunology*
  • Autoantibodies / blood
  • Autoantibodies / immunology*
  • Cohort Studies
  • Disease Susceptibility / immunology
  • Enzyme-Linked Immunosorbent Assay
  • Ethnicity
  • Female
  • Humans
  • Male
  • Racial Groups

Substances

  • Amyloid beta-Peptides
  • Autoantibodies